FDA recently approved methylphenidate hydrochloride extended-release capsules (LA) CII, USP, the generic equivalent of Ritalin LA. Actavis Group, an international generic pharmaceuticals company, received first-to-file exclusivity on the 20-mg, 30-mg, and 40-mg strengths.
FDA recently approved methylphenidate hydrochloride extended-release capsules (LA) CII, USP, the generic equivalent of Ritalin LA. Actavis Group, an international generic pharmaceuticals company, received first-to-file exclusivity on the 20-mg, 30-mg, and 40-mg strengths.
Distribution of the product has begun in the United States.
Methylphenidate hydrochloride extended-release capsules (20 mg, 30 mg, and 40 mg) had U.S. sales of approximately $80.7 million for the 12 months ending September 30, 2011, according to IMS Health.
Doug Boothe, CEO of Actavis in the United States, said in a press release: “The approval and launch of methylphenidate hydrochloride extended-release capsules (LA) offers a significant value to our customers and patients. This approval, along with the first-to-file exclusivity, also underscores Actavis’ emphasis and commitment to bringing complex controlled-release products to the marketplace.”
Prescribing information is available at the Actavis website.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.